Michael J Mccabe, 721513 Race St UNIT 3622, Philadelphia, PA 19102

2003015, Aug 21, 2003

Dec 13, 2002

10/319796

Michael McCabe - Villanova PA, US

F23C007/00

431/187000

A pulverized fuel burner having reduced NOemissions comprises a first precessing jet nozzle surrounded by a second nozzle. The second nozzle feeds pulverized fuel into a precessing jet of air formed by the first nozzle.

2005028, Dec 29, 2005

Jun 29, 2005

11/171963

Robin Forster - Philadelphia PA, US
Alexander Guyse - King of Prussia PA, US
Michael McCabe - Berwyn PA, US

Cemex Inc. - Houston TX

F27B015/00
F23L001/00

110345000, 110297000

A method and apparatus are disclosed for reducing total NOx emissions from a cement kiln. The method includes the step of injecting water into the flame of the kiln at a point proximate the initial ignition point of the burner. The apparatus includes an injection nozzle for injecting water into the burner flame. Also disclosed is an improved process for making cement clinker. The process includes the steps of burning fuel to generate a flame within a kiln, injecting water into the flame to control formation of nitrogen oxides within the kiln, introducing a mixture of cement raw materials into the kiln, and reacting the raw materials to form cement clinker.

2017034, Dec 7, 2017

Jun 7, 2017

15/616306

- Wilmington DE, US
Gopinath GANJI - Collegeville PA, US
Michael T. MCCABE - Collegeville PA, US
Kimberly N. SMITHEMAN - Collegeville PA, US

A61K 31/496
G01N 33/574
A61K 45/06
C12Q 1/68

This invention relates to methods of treating cancer in a subject in need thereof, e.g., in a human in need thereof, comprising determining at least one of the following in a sample from said human: (a) the presence or absence of a mutation at the alanine 677 (A677) residue in EZH2 in a sample from said human; or (b) the presence or absence of a mutation at the tyrosine 641 (Y641) residue in EZH2; or (c) the presence or absence of an increased level of H3K27me3 as compared to a control, and administering to said human an effective amount of an EZH2 inhibitor or a pharmaceutically acceptable salt thereof if at least one of said A677 mutation, Y641 mutation, or increased level of H3K27me3 is present in said sample

2017010, Apr 20, 2017

Mar 21, 2015

15/127873

- Evanston IL, US
- Brentford, Middlesex, GB
Michael McCABE - Collegeville PA, US
Relja POPOVIC - Evanston IL, US

A61K 31/5377
A61K 31/496
A61K 45/06

Disclosed are methods for treating cancer such as a myeloid malignancy such as multiple myeloma in a human using EZH2 inhibitors in human populations having a translocation MMSET or a decreased level of a functional UTX protein or both.

2014037, Dec 25, 2014

Sep 30, 2012

14/346359

- Wilmington DE, US
Gopinath Ganji - Collegeville PA, US
Michael T. McCabe - Collegeville PA, US
Kimberly N. Smitheman - Collegeville PA, US

A61K 31/496
C12Q 1/68
G01N 33/574

51425309, 435 611, 435 74, 435 792, 506 9, 506 16

This invention relates to methods of treating cancer in a subject such as a human and determining at least one of the following in a sample from the subject, such as a human: (a) the presence or absence of a mutation at the alanine 677 (A677) residue in EZH2; or (b) the presence or absence of a mutation at the tyrosine 641 (Y641) residue in EZH2; or (c) the presence or absence of an increased level of H3K27me3 as compared to a control, and administering to said human an effective amount of an EZH2 inhibitor or a pharmaceutically acceptable salt thereof if at least one of the A677 mutation, Y641 mutation, or increased level of H3K27me3 is present in the sample.